Top

Published in:

01-11-2008 | Therapy In Practice

Treatment Strategies for Methicillin-Resistant Staphylococcus aureus Infections in Pediatrics

Authors: Dr Jason G. Newland, Gregory L. Kearns

Published in: Pediatric Drugs | Issue 6/2008

Abstract

Staphylococcus aureus is an important pathogen that frequently causes clinical disease in children. A wide array of illnesses can be caused by this common pathogen ranging from non-invasive skin infections to severe, life-threatening sepsis. Additionally, as antibacterials have been used to eradicate S. aureus, it has developed resistance to these important therapeutic agents. Methicillin-resistant S. aureus (MRSA) has become an increasing problem in pediatric patients over the past decade. In this review, we discuss the epidemiology, pathogenesis, and treatment options available in treating MRSA infections in children. Specifically, we address the importance of abscess drainage in the treatment of skin and soft tissue infections, the most common clinical manifestation of MRSA infections, and highlight the various agents that are available for treating this common infection. In severe, life-threatening invasive MRSA infections the primary therapeutic option is vancomycin. In cases of MRSA toxic shock syndrome the addition of clindamycin is necessary. In other invasive MRSA infections, such as pneumonia and musculoskeletal infections, the empiric treatment of choice is clindamycin. Finally, newer agents and additional treatment options are discussed.

Rammelkamp CH, Maxon T. Resistance of Staphylococcus aureus to the action of penicillin. Proc Soc Exp Biol Med 1942; 51: 386

Jevons MP, Coe AW, Parker MT. Methicillin resistance in staphylococci. Lancet 1963; 1: 904–7PubMedCrossRef

Layton MC, Hierholzer Jr WJ, Patterson JE. The evolving epidemiology of methicillin-resistant Staphylococcus aureus at a university hospital. Infect Control Hosp Epidemiol 1995; 16: 12–7PubMedCrossRef

Coello R, Glynn JR, Gaspar C, et al. Risk factors for developing clinical infection with methicillin-resistant Staphylococcus aureus (MRSA) amongst hospital patients initially only colonized with MRSA. J Hosp Infect 1997; 37: 39–46PubMedCrossRef

Davis KA, Stewart JJ, Crouch HK, et al. Methicillin-resistant Staphylococcus aureus (MRSA) nares colonization at hospital admission and its effect on subsequent MRSA infection. Clin Infect Dis 2004; 39: 776–82PubMedCrossRef

Roghmann MC, Siddiqui A, Plaisance K, et al. MRSA colonization and the risk of MRSA bacteraemia in hospitalized patients with chronic ulcers. J Hosp Infect 2001; 47: 98–103PubMedCrossRef

Campbell AL, Bryant KA, Stover B, et al. Epidemiology of methicillin-resistant Staphylococcus aureus at a children’s hospital. Infect Control Hosp Epidemiol 2003; 24: 427–30PubMedCrossRef

Purcell K, Fergie J. Epidemic of community-acquired methicillin-resistant Staphylococcus aureus infections: a 14-year study at Driscoll Children’s Hospital. Arch Pediatr Adolesc Med 2005; 159: 980–5PubMedCrossRef

Herold BC, Immergluck LC, Maranan MC, et al. Community-acquired methicillin-resistant Staphylococcus aureus in children with no identified predisposing risk. Jama 1998; 279: 593–8PubMedCrossRef

10.

Methicillin-resistant Staphylococcus aureus infections in correctional facilities-Georgia, California, and Texas, 2001–2003. MMWR Morb Mortal Wkly Rep 2003; 52: 992–6

11.

Shahin R, Johnson IL, Jamieson F, et al. Methicillin-resistant Staphylococcus aureus carriage in a child care center following a case of disease. Toronto Child Care Center Study Group. Arch Pediatr Adolesc Med 1999; 153: 864–8PubMed

12.

Zinderman CE, Conner B, Malakooti MA, et al. Community-acquired methicillin-resistant Staphylococcus aureus among military recruits. Emerg Infect Dis 2004; 10: 941–4PubMedCrossRef

13.

Community-associated methicillin-resistant Staphylococcus aureus infection among healthy newborns: Chicago and Los Angeles County, 2004. MMWR 2006; 55: 329–32

14.

Fridkin SK, Hageman JC, Morrison M, et al. Methicillin-resistant Staphylococcus aureus disease in three communities. N Engl J Med 2005; 352: 1436–44PubMedCrossRef

15.

Hulten KG, Kaplan SL, Gonzalez BE, et al. Three-year surveillance of community onset health care-associated Staphylococcus aureus infections in children. Pediatr Infect Dis J 2006; 25: 349–53PubMedCrossRef

16.

Zaoutis TE, Toltzis P, Chu J, et al. Clinical and molecular epidemiology of community-acquired methicillin-resistant Staphylococcus aureus infections among children with risk factors for health care-associated infection: 2001–2003. Pediatr Infect Dis J 2006; 25: 343–8PubMedCrossRef

17.

European antimicrobial resistance surveillance system (database). European Commission’s Directorate-General for Health and Consumer Affairs (DG SANCO) and the Dutch Ministry of Health, Welfare and Sport 2008 [online]. Available from URL: http://www.rivm.nl/earss/ [Accessed 2008 Jan 31]

18.

Klevens RM, Morrison MA, Nadle J, et al. Invasive methicillin-resistant Staphylococcus aureus infections in the United States. JAMA 2007; 298: 1763–71PubMedCrossRef

19.

Hartman B, Tomasz A. Altered penicillin-binding proteins in methicillin-resistant strains of Staphylococcus aureus. Antimicrob Agents Chemother 1981; 19: 726–35PubMedCrossRef

20.

Deresinski S. Methicillin-resistant Staphylococcus aureus: an evolutionary, epidemiologic, and therapeutic odyssey. Clin Infect Dis 2005; 40: 562–73PubMedCrossRef

21.

Chen AE, Goldstein M, Carroll K, et al. Evolving epidemiology of pediatric Staphylococcus aureus cutaneous infections in a baltimore hospital. Pediatr Emerg Care 2006; 22: 717–23PubMedCrossRef

22.

Kaplan SL, Hulten KG, Gonzalez BE, et al. Three-year surveillance of community-acquired Staphylococcus aureus infections in children. Clin Infect Dis 2005; 40: 1785–91PubMedCrossRef

23.

Sattler CA, Correa AG. Coagulase-positive staphylococcal infections (Staphylococcus aureus). In: Feigin RD, Cherry JD, Demmler GJ, et al., editors. Textbook of pediatric infectious diseases. 5th ed. Philadelphia (PA): Saunders, 2004: 1099–129

24.

Gonzalez BE, Hulten KG, Dishop MK, et al. Pulmonary manifestations in children with invasive community-acquired Staphylococcus aureus infection. Clin Infect Dis 2005; 41: 583–90PubMedCrossRef

25.

Labandeira-Rey M, Couzon F, Boisset S, et al. Staphylococcus aureus Panton-Valentine leukocidin causes necrotizing pneumonia. Science 2007; 315: 1130–3PubMedCrossRef

26.

Voyich JM, Otto M, Mathema B, et al. Is Panton-Valentine leukocidin the major virulence determinant in community-associated methicillin-resistant Staphylococcus aureus disease? J Infect Dis 2006; 194: 1761–70PubMedCrossRef

27.

Gillet Y, Issartel B, Vanhems P, et al. Association between Staphylococcus aureus strains carrying gene for Panton-Valentine leukocidin and highly lethal necrotising pneumonia in young immunocompetent patients. Lancet 2002; 359: 753–9PubMedCrossRef

28.

Martinez-Aguilar G, Avalos-Mishaan A, Hulten K, et al. Community-acquired, methicillin-resistant and methicillin-susceptible Staphylococcus aureus musculoskeletal infections in children. Pediatr Infect Dis J 2004; 23: 701–6PubMedCrossRef

29.

Shurland S, Zhan M, Bradham DD, et al. Comparison of mortality risk associated with bacteremia due to methicillin-resistant and methicillin-susceptible Staphylococcus aureus. Infect Control Hosp Epidemiol 2007; 28: 273–9PubMedCrossRef

30.

Sattler CA, Mason Jr EO, Kaplan SL. Prospective comparison of risk factors and demographic and clinical characteristics of community-acquired, methicillin-resistant versus methicillin-susceptible Staphylococcus aureus infection in children. Pediatr Infect Dis J 2002; 21: 910–7PubMedCrossRef

31.

Buckingham SC, McDougal LK, Cathey LD, et al. Emergence of community-associated methicillin-resistant Staphylococcus aureus at a Memphis, Tennessee children’s hospital. Pediatr Infect Dis J 2004; 23: 619–24PubMedCrossRef

32.

Fergie JE, Purcell K. Community-acquired methicillin-resistant Staphylococcus aureus infections in South Texas children. Pediatr Infect Dis J 2001; 20: 860–3PubMedCrossRef

33.

Lee MC, Rios AM, Aten MF, et al. Management and outcome of children with skin and soft tissue abscesses caused by community-acquired methicillin-resistant Staphylococcus aureus. Pediatr Infect Dis J 2004; 23: 123–7PubMedCrossRef

34.

Gonzalez BE, Martinez-Aguilar G, Hulten KG, et al. Severe staphylococcal sepsis in adolescents in the era of community-acquired methicillin-resistant Staphylococcus aureus. Pediatrics 2005; 115: 642–8PubMedCrossRef

35.

Ochoa TJ, Mohr J, Wanger A, et al. Community-associated methicillin-resistant Staphylococcus aureus in pediatric patients. Emerg Infect Dis 2005; 11: 966–8PubMedCrossRef

36.

Miles F, Voss L, Segedin E, et al. Review of Staphylococcus aureus infections requiring admission to a paediatric intensive care unit. Arch Dis Child 2005; 90: 1274–8PubMedCrossRef

37.

Four pediatric deaths from community-acquired methicillin-resistant Staphylococcus aureus: Minnesota and North Dakota, 1997–1999. MMWR Morb Mortal Wkly Rep 1999; 48: 707–10

38.

Mongkolrattanothai K, Boyle S, Kahana MD, et al. Severe Staphylococcus aureus infections caused by clonally related community-acquired methicillin-susceptible and methicillin-resistant isolates. Clin Infect Dis 2003; 37: 1050–8PubMedCrossRef

39.

Severe methicillin-resistant Staphylococcus aureus community-acquired pneumonia associated with influenza: Louisiana and Georgia, December 2006-January 2007. MMWR Morb Mortal Wkly Rep 2007; 56: 325–9

40.

Chi CY, Wang SM, Lin HC, et al. A clinical and microbiological comparison of Staphylococcus aureus toxic shock and scalded skin syndromes in children. Clin Infect Dis 2006; 42: 181–5PubMedCrossRef

41.

Durand G, Bes M, Meugnier H, et al. Detection of new methicillin-resistant Staphylococcus aureus clones containing the toxic shock syndrome toxin 1 gene responsible for hospital- and community-acquired infections in France. J Clin Microbiol 2006; 44: 847–53PubMedCrossRef

42.

Haddadin DW, Samnani IQ, Moorman JP. Drotrecogin alfa (activated) for nonmenstrual toxic shock syndrome associated with methicillin-resistant Staphylococcus aureus infection. South Med J 2006; 99: 1295–6PubMedCrossRef

43.

Davis JP, Chesney PJ, Wand PJ, et al. Toxic-shock syndrome: epidemiologic features, recurrence, risk factors, and prevention. N Engl J Med 1980; 303: 1429–35PubMedCrossRef

44.

Shands KN, Schmid GP, Dan BB, et al. Toxic-shock syndrome in menstruating women: association with tampon use and Staphylococcus aureus and clinical features in 52 cases. N Engl J Med 1980; 303: 1436–42PubMedCrossRef

45.

Nakano M, Miyazawa H, Kawano Y, et al. An outbreak of neonatal toxic shock syndrome-like exanthematous disease (NTED) caused by methicillin-resistant Staphylococcus aureus (MRSA) in a neonatal intensive care unit. Microbiol Immunol 2002; 46: 277–84PubMed

46.

Wharton M, Chorba TL, Vogt RL, et al. Case definitions for public health surveillance. MMWR Recomm Rep 1990; 39: 1–43PubMed

47.

Chuang YY, Huang YC, Lin TY. Toxic shock syndrome in children: epidemiology, pathogenesis, and management. Paediatr Drugs 2005; 7: 11–25PubMedCrossRef

48.

Hageman JC, Uyeki TM, Francis JS, et al. Severe community-acquired pneumonia due to Staphylococcus aureus, 2003–04 influenza season. Emerg Infect Dis 2006; 12: 894–9PubMedCrossRef

49.

Gorenstein A, Gross E, Houri S, et al. The pivotal role of deep vein thrombophlebitis in the development of acute disseminated staphylococcal disease in children [abstract]. Pediatrics 2000; 106: E87PubMedCrossRef

50.

Campbell JA, Gastineau DC, Velios F. Roentgen studies in suppurative pneumonia of infants and children. JAMA 1954; 154: 468–72CrossRef

51.

Krogstad P. Osteomyelitis and septic arthritis. In: Feigin RD, Cherry JD, Demmler GJ, et al., editors. Textbook of pediatric infectious diseases. 5th ed. Philadelphia (PA): Saunders, 2004: 713–29

52.

Arnold SR, Elias D, Buckingham SC, et al. Changing patterns of acute hematogenous osteomyelitis and septic arthritis: emergence of community-associated methicillin-resistant Staphylococcus aureus. J Pediatr Orthop 2006; 26: 703–8PubMedCrossRef

53.

Dich VQ, Nelson JD, Haltalin KC. Osteomyelitis in infants and children: a review of 163 cases. Am J Dis Child 1975; 129: 1273–8PubMed

54.

Borella L, Goobar JE, Summitt RL, et al. Septic arthritis in childhood. J Pediatr 1963; 62: 742–7PubMedCrossRef

55.

Pannaraj PS, Hulten KG, Gonzalez BE, et al. Infective pyomyositis and myositis in children in the era of community-acquired, methicillin-resistant Staphylococcus aureus infection. Clin Infect Dis 2006; 43: 953–60PubMedCrossRef

56.

Fowler Jr VG, Sanders LL, Kong LK, et al. Infective endocarditis due to Staphylococcus aureus: 59 prospectively identified cases with follow-up. Clin Infect Dis 1999; 28: 106–14PubMedCrossRef

57.

Baddour LM, Wilson WR, Bayer AS, et al. Infective endocarditis: diagnosis, antimicrobial therapy, and management of complications. A statement for healthcare professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, and the Councils on Clinical Cardiology, Stroke, and Cardiovascular Surgery and Anesthesia, American Heart Association. Endorsed by the Infectious Diseases Society of America. Circulation 2005; 111: e394–434PubMedCrossRef

58.

Starke JR. Infective endocarditis. In: Feigin RD, Cherry JD, Demmler GJ, et al., editors. Textbook of pediatric infectious diseases. 5th ed. Philadelphia (PA): Saunders, 2004: 355–80

59.

Durack DT, Lukes AS, Bright DK. New criteria for diagnosis of infective endocarditis: utilization of specific echocardiographic findings. Duke Endocarditis Service. Am J Med 1994; 96: 200–9PubMedCrossRef

60.

Hwang JH, Tsai HY, Liu TC. Community-acquired methicillin-resistant Staphylococcus aureus infections in discharging ears. Acta Otolaryngol 2002; 122: 827–30PubMedCrossRef

61.

Huang WH, Hung PK. Methicillin-resistant Staphylococcus aureus infections in acute rhinosinusitis. Laryngoscope 2006; 116: 288–91PubMedCrossRef

62.

Jones R, Santos JI, Overall JC, et al. Bacterial tracheitis. Jama 1979; 242: 721–6PubMedCrossRef

63.

Liston SL, Gehrz RC, Siegel LG, et al. Bacterial tracheitis. Am J Dis Child 1983; 137: 764–7PubMed

64.

Goodkin HP, Pomeroy SL. Parameningeal infections. In: Feigin RD, Cherry JD, Demmler GJ, et al., editors. Textbook of pediatric infectious diseases. 5th ed. Philadelphia (PA): Saunders, 2004: 475–83

65.

McGirt MJ, Zaas A, Fuchs HE, et al. Risk factors for pediatric ventriculoperitoneal shunt infection and predictors of infectious pathogens. Clin Infect Dis 2003; 36: 858–62PubMedCrossRef

66.

Laupland KB, Conly JM. Treatment of Staphylococcus aureus colonization and prophylaxis for infection with topical intranasal mupirocin: an evidence-based review. Clin Infect Dis 2003; 37: 933–8PubMedCrossRef

67.

Simor AE, Phillips E, McGeer A, et al. Randomized controlled trial of chlorhexidine gluconate for washing, intranasal mupirocin, and rifampin and doxycycline versus no treatment for the eradication of methicillin-resistant Staphylococcus aureus colonization. Clin Infect Dis 2007; 44: 178–85PubMedCrossRef

68.

Chesney PJ. Cervical lymphadenitis and neck infections. In: Long SS, Pickering LK, Prober CG, editors. Principles and practice of pediatric infectious diseases. Philadelphia (PA): Churchill Livingstone, 2003: 165–76

69.

Staphylococcus aureus resistant to vancomycin: United States, 2002. MMWR Morb Mortal Wkly Rep 2002; 51: 565–7

70.

Hiramatsu K. Vancomycin-resistant Staphylococcus aureus: a new model of antibiotic resistance. Lancet Infect Dis 2001; 1: 147–55PubMedCrossRef

71.

Staphylococcus aureus with reduced susceptibility to vancomycin-United States, 1997. MMWR Morb Mortal Wkly Rep 1997 Aug 22; 46(33): 765–6

72.

Cosgrove SE, Carroll KC, Perl TM. Staphylococcus aureus with reduced susceptibility to vancomycin. Clin Infect Dis 2004; 39: 539–45PubMedCrossRef

73.

Fridkin SK, Hageman J, McDougal LK, et al. Epidemiological and microbiological characterization of infections caused by Staphylococcus aureus with reduced susceptibility to vancomycin, United States, 1997–2001. Clin Infect Dis 2003; 36: 429–39PubMedCrossRef

74.

Yogev R, Patterson LE, Kaplan SL, et al. Linezolid for the treatment of complicated skin and skin structure infections in children. Pediatr Infect Dis J 2003; 22: S172–7PubMedCrossRef

75.

McKinnon PS, Sorensen SV, Liu LZ, et al. Impact of linezolid on economic outcomes and determinants of cost in a clinical trial evaluating patients with MRSA complicated skin and soft-tissue infections. Ann Pharmacother 2006; 40: 1017–23PubMedCrossRef

76.

Sharpe JN, Shively EH, Polk HC, et al. Clinical and economic outcomes of oral linezolid versus intravenous vancomycin in the treatment of MRSA-complicated, lower-extremity skin and soft-tissue infections caused by methicillin-resistant Staphylococcus aureus. Am J Surg 2005; 189: 425–8PubMedCrossRef

77.

Gales AC, Sader HS, Andrade SS, et al. Emergence of linezolid-resistant Staphylococcus aureus during treatment of pulmonary infection in a patient with cystic fibrosis. Int J Antimicrob Agents 2006; 27: 300–2PubMedCrossRef

78.

Roberts SM, Freeman AF, Harrington SM, et al. Linezolid-resistant Staphylococcus aureus in two pediatric patients receiving low-dose linezolid therapy. Pediatr Infect Dis J 2006; 25: 562–4PubMedCrossRef

79.

Meka VG, Gold HS, Cooke A, et al. Reversion to susceptibility in a linezolid-resistant clinical isolate of Staphylococcus aureus. J Antimicrob Chemother 2004; 54: 818–20PubMedCrossRef

80.

Ruhe JJ, Monson T, Bradsher RW, et al. Use of long-acting tetracyclines for methicillin-resistant Staphylococcus aureus infections: case series and review of the literature. Clin Infect Dis 2005; 40: 1429–34PubMedCrossRef

81.

Smith SM, Eng RH, Tecson-Tumang F. Ciprofloxacin therapy for methicillin-resistant Staphylococcus aureus infections or colonizations. Antimicrob Agents Chemother 1989; 33: 181–4PubMedCrossRef

82.

Takizawa T, Hashimoto K, Minami T, et al. The comparative arthropathy of fluoroquinolones in dogs. Hum Exp Toxicol 1999; 18: 392–9PubMedCrossRef

83.

Namdar R, Morris AB, Peloquin CA. Rifamycins for nonmycobacterial infections. In: McKinnon PS, Peloquin CA, Morse G, editors. Antimicrobial therapy and vaccines. Pittsburgh (PA): ESun Technologies, LLC, 2002: 403–53

84.

Burnie J, Matthews R, Jiman-Fatami A, et al. Analysis of 42 cases of septicemia caused by an epidemic strain of methicillin-resistant Staphylococcus aureus: evidence of resistance to vancomycin. Clin Infect Dis 2000; 31: 684–9PubMedCrossRef

85.

Tan TQ, Mason Jr EO, Ou CN, et al. Use of intravenous rifampin in neonates with persistent staphylococcal bacteremia. Antimicrob Agents Chemother 1993; 37: 2401–6PubMedCrossRef

86.

Kaplan SL, Deville JG, Yogev R, et al. Linezolid versus vancomycin for treatment of resistant gram-positive infections in children. Pediatr Infect Dis J 2003; 22: 677–86PubMedCrossRef

87.

Kohno S, Yamaguchi K, Aikawa N, et al. Linezolid versus vancomycin for the treatment of infections caused by methicillin-resistant Staphylococcus aureus in Japan. J Antimicrob Chemother 2007; 60: 1361–9PubMedCrossRef

88.

Kurt BA, Winterhalter KM, Connors RH, et al. Therapy of parapneumonic effusions in children: video-assisted thoracoscopic surgery versus conventional thoracostomy drainage. Pediatrics 2006; 118: e547–53PubMedCrossRef

89.

Schultz KD, Fan LL, Pinsky J, et al. The changing face of pleural empyemas in children: epidemiology and management. Pediatrics 2004; 113: 1735–40PubMedCrossRef

90.

Sonnappa S, Cohen G, Owens CM, et al. Comparison of urokinase and videoassisted thoracoscopic surgery for treatment of childhood empyema. Am J Respir Crit Care Med 2006; 174: 221–7PubMedCrossRef

91.

Akins RL, Coyle EA, Levison ME, et al. Clindamycin. In: Yu VL, Edwards G, McKinnon PS, et al., editors. Antimicrobial therapy and vaccines. 2nd ed. Pittsburgh (PA): ESun Technologies, LLC, 2002: 131–47

92.

Mazur D, Schug BS, Evers G, et al. Bioavailability and selected pharmacokinetic parameters of clindamycin hydrochloride after administration of a new 600 mg tablet formulation. Int J Clin Pharmacol Ther 1999; 37: 386–92PubMed

93.

Cruciani M, Gatti G, Lazzarini L, et al. Penetration of vancomycin into human lung tissue. J Antimicrob Chemother 1996; 38: 865–9PubMedCrossRef

94.

Lamer C, de Beco V, Soler P, et al. Analysis of vancomycin entry into pulmonary lining fluid by bronchoalveolar lavage in critically ill patients. Antimicrob Agents Chemother 1993; 37: 281–6PubMedCrossRef

95.

Gee T, Ellis R, Marshall G, et al. Pharmacokinetics and tissue penetration of linezolid following multiple oral doses. Antimicrob Agents Chemother 2001; 45: 1843–6PubMedCrossRef

96.

Kaplan SL, Patterson L, Edwards KM, et al. Linezolid for the treatment of community-acquired pneumonia in hospitalized children. Linezolid pediatric pneumonia study group. Pediatr Infect Dis J 2001; 20: 488–94PubMedCrossRef

97.

Stevens DL, Herr D, Lampiris H, et al. Linezolid versus vancomycin for the treatment of methicillin-resistant Staphylococcus aureus infections. Clin Infect Dis 2002; 34: 1481–90PubMedCrossRef

98.

Goldstein FW, Stein GE. Trimethoprim and trimethoprim-sulfamethoxazole (cotrimoxazole). In: McKinnon PS, Peloquin CA, Morse G, editors. Antimicrobial therapy and vaccines. 2nd ed. Pittsburgh (PA): ESun Technologies, LLC, 2002: 485–99

99.

Graziani AL, Lawson LA, Gibson GA, et al. Vancomycin concentrations in infected and noninfected human bone. Antimicrob Agents Chemother 1988; 32: 1320–2PubMedCrossRef

100.

Yeldandi V, Strodtman R, Lentino JR. In-vitro and in-vivo studies of trimethoprim-sulphamethoxazole against multiple resistant Staphylococcus aureus. J Antimicrob Chemother 1988; 22: 873–80PubMedCrossRef

101.

Howden BP, Ward PB, Charles PG, et al. Treatment outcomes for serious infections caused by methicillin-resistant Staphylococcus aureus with reduced vancomycin susceptibility. Clin Infect Dis 2004; 38: 521–8PubMedCrossRef

102.

Patel R, Piper KE, Rouse MS, et al. Linezolid therapy of Staphylococcus aureus experimental osteomyelitis. Antimicrob Agents Chemother 2000; 44: 3438–40PubMedCrossRef

103.

Cremieux AC, Maziere B, Vallois JM, et al. Evaluation of antibiotic diffusion into cardiac vegetations by quantitative autoradiography. J Infect Dis 1989; 159: 938–44PubMedCrossRef

104.

Levine DP, Fromm BS, Reddy BR. Slow response to vancomycin or vancomycin plus rifampin in methicillin-resistant Staphylococcus aureus endocarditis. Ann Intern Med 1991; 115: 674–80PubMed

105.

Rybak MJ, Bailey EM, Lamp KC, et al. Pharmacokinetics and bactericidal rates of daptomycin and vancomycin in intravenous drug abusers being treated for gram-positive endocarditis and bacteremia. Antimicrob Agents Chemother 1992; 36: 1109–14PubMedCrossRef

106.

Small PM, Chambers HF. Vancomycin for Staphylococcus aureus endocarditis in intravenous drug users. Antimicrob Agents Chemother 1990; 34: 1227–31PubMedCrossRef

107.

Miyamoto S, Hadama T, Tanaka H, et al. MRSA aortic valve endocarditis treated by pericardium-lined dacron patch and vancomycin-containing fibrin glue. Ann Thorac Cardiovasc Surg 2004; 10: 252–4PubMed

108.

Watanakunakorn C. Clindamycin therapy of Staphylococcus aureus endocarditis: clinical relapse and development of resistance to clindamycin, lincomycin and erythromycin. Am J Med 1976; 60: 419–25PubMedCrossRef

109.

de Gorgolas M, Aviles P, Verdejo C, et al. Treatment of experimental endocarditis due to methicillin-susceptible or methicillin-resistant Staphylococcus aureus with trimethoprim-sulfamethoxazole and antibiotics that inhibit cell wall synthesis. Antimicrob Agents Chemother 1995; 39: 953–7PubMedCrossRef

110.

Markowitz N, Quinn EL, Saravolatz LD. Trimethoprim-sulfamethoxazole compared with vancomycin for the treatment of Staphylococcus aureus infection. Ann Intern Med 1992; 117: 390–8PubMed

111.

Dailey CF, Dileto-Fang CL, Buchanan LV, et al. Efficacy of linezolid in treatment of experimental endocarditis caused by methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 2001; 45: 2304–8PubMedCrossRef

112.

Chiang FY, Climo M. Efficacy of linezolid alone or in combination with vancomycin for treatment of experimental endocarditis due to methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 2003; 47: 3002–4PubMedCrossRef

113.

Jantausch BA, Deville J, Adler S, et al. Linezolid for the treatment of children with bacteremia or nosocomial pneumonia caused by resistant gram-positive bacterial pathogens. Pediatr Infect Dis J 2003; 22: S164–71PubMedCrossRef

114.

Houlihan HH, Mercier RC, Rybak MJ. Pharmacodynamics of vancomycin alone and in combination with gentamicin at various dosing intervals against methicillin-resistant Staphylococcus aureus-infected fibrin-platelet clots in an in vitro infection model. Antimicrob Agents Chemother 1997; 41: 2497–501PubMed

115.

LaPlante KL, Rybak MJ. Impact of high-inoculum Staphylococcus aureus on the activities of nafcillin, vancomycin, linezolid, and daptomycin, alone and in combination with gentamicin, in an in vitro pharmacodynamic model. Antimicrob Agents Chemother 2004; 48: 4665–72PubMedCrossRef

116.

Mermel LA, Farr BM, Sherertz RJ, et al. Guidelines for the management of intravascular catheter-related infections. Clin Infect Dis 2001; 32: 1249–72PubMedCrossRef

117.

Breedt J, Teras J, Gardovskis J, et al. Safety and efficacy of tigecycline in treatment of skin and skin structure infections: results of a double-blind phase 3 comparison study with vancomycin-aztreonam. Antimicrob Agents Chemother 2005; 49: 4658–66PubMedCrossRef

118.

Jauregui LE, Babazadeh S, Seltzer E, et al. Randomized, double-blind comparison of once-weekly dalbavancin versus twice-daily linezolid therapy for the treatment of complicated skin and skin structure infections. Clin Infect Dis 2005; 41: 1407–15PubMedCrossRef

119.

Martone WJ, Lamp KC. Efficacy of daptomycin in complicated skin and skinstructure infections due to methicillin-sensitive and -resistant Staphylococcus aureus: results from the core registry. Curr Med Res Opin 2006; 22: 2337–43PubMedCrossRef

120.

Noel GJ. Clinical profile of ceftobiprole, a novel beta-lactam antibiotic. Clin Microbiol Infect 2007; 13Suppl. 2: 25–9PubMedCrossRef

121.

Nichols RL, Graham DR, Barriere SL, et al. Treatment of hospitalized patients with complicated gram-positive skin and skin structure infections: two randomized, multicentre studies of quinupristin/dalfopristin versus cefazolin, oxacillin or vancomycin. Synercid Skin and Skin Structure Infection Group. J Antimicrob Chemother 1999; 44: 263–73PubMedCrossRef

122.

Loeffler AM, Drew RH, Perfect JR, et al. Safety and efficacy of quinupristin/dalfopristin for treatment of invasive gram-positive infections in pediatric patients. Pediatr Infect Dis J 2002; 21: 950–6PubMedCrossRef

123.

Fowler Jr VG, Boucher HW, Corey GR, et al. Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus. N Engl J Med 2006; 355: 653–65PubMedCrossRef

124.

Maclayton DO, Hall RG, 2nd. Pharmacologic treatment options for nosocomial pneumonia involving methicillin-resistant Staphylococcus aureus. Ann Pharmacother 2007; 41: 235–44PubMedCrossRef

125.

Silverman JA, Mortin LI, Vanpraagh AD, et al. Inhibition of daptomycin by pulmonary surfactant: in vitro modeling and clinical impact. J Infect Dis 2005; 191: 2149–52PubMedCrossRef

126.

Kearns GL, Jacobs RF, Jafri HS, et al. Pharmokinetics of daptomycin in pediatric patients [abstract]. Proceedings of the Pediatric Academic Societies’ Annual Meeting; 2007 May 5–8; Toronto (ON)

127.

Kearns GL, Abdel-Rahman SM, Alander SW, et al. Developmental pharmacology: drug disposition, action, and therapy in infants and children. N Engl J Med 2003; 349: 1157–67PubMedCrossRef

Title: Treatment Strategies for Methicillin-Resistant Staphylococcus aureus Infections in Pediatrics
Authors: Dr Jason G. Newland
Gregory L. Kearns
Publication date: 01-11-2008
Publisher: Springer International Publishing
Published in: Pediatric Drugs / Issue 6/2008
Print ISSN: 1174-5878
Electronic ISSN: 1179-2019
DOI: https://doi.org/10.2165/0148581-200810060-00004

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Treatment Strategies for Methicillin-Resistant Staphylococcus aureus Infections in Pediatrics

Abstract

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 6/2008

DTaP-IPV/Hib Vaccine (Pentacel®)

Management of Acute Kidney Injury in Children

Probability of Achieving Requisite Pharmacodynamic Exposure for Oral β-Lactam Regimens against Haemophilus influenzae in Children

Establishing Causality of CNS Depression in Breastfed Infants Following Maternal Codeine Use

Drug Delivery Systems in Children

Acknowledgment